FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
WALTHAM, Mass., Oct. 24, 2016 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The three conferences are:
- The Credit Suisse 25th Annual Healthcare Conference at The Phoenician in Scottsdale, Arizona on Monday, November 7 and Tuesday, November 8. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, will present on November 8 at 8:30 AM MT and will also host meetings with investors.
- The Global Mizuho Investor Conference at The Omni Berkshire Place in New York, New York on Monday, November 14. Tim Pearson, EVP and CFO of TESARO, will participate in meetings with investors.
- The Raymond James Boston Fall Investors Conference at The State Room in Boston, Massachusetts on Tuesday, November 15. Tim Pearson, EVP and CFO of TESARO, will participate in meetings with investors.
A live webcast of the presentation at the Credit Suisse conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conference.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
